cognitive cybersecurity intelligence
Abivax is ringing in the new year with a pivotal Phase III program underway for its lead candidate obefazimod in moderate to severe ulcerative colitis (UC), the first of three indications for which the Paris-based biopharma is developing the oral small molecule.
The global Phase III…
Source: www.genengnews.com – Read more
Subscribe to HEAL Security Dispatch for the latest healthcare cybersecurity news and analysis.
SECURITY AFFAIRS MALWARE NEWSLETTER ROUND 63 Security Affairs
The cybersecurity landscape has seen a substantial threat vector transformation. While malware and ransomware continue to be relevant threats, a more nuanced class of attacks
Leading in healthcare when the odds are stacked against you is not about eliminating the challenges. It is about meeting them without losing sight of
A dangerous truth is hidden behind the winning smiles and cartoon-adorned walls at pediatric dental offices: Children are dying or suffering from debilitating neurologic injury
